Recent research have centered on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and dopamine neurotransmission. While GCGR agonists are commonly employed for treating type 2 diabetes mellitus, their unexpected impacts on reinforcement circuits, specifically influenced by dopaminergic networks, are gaining substantial interest. Th